Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Websitetri-takeda.com
Phone+1 650 328 2900
Emailcontact@tri-taked...
Employees
Founded2001

Funds

Offices

Palo Alto, USA
435 Tasso Street, Suite 300
Palo Alto, CA, 94301
USA

People

President & CEO
Senior Investment Director
Senior Investment Director

Tags

Takeda Ventures

TVI’s mission is to identify, help create and support the development of therapeutic innovation that aligns with Takeda’s own strategic imperatives. We do this by investing in technology and product concepts, and highly effective teams that can turn ideas into reality. Our primary focus is on medium to longer term returns in the form of product and technology successes for our portfolio companies and capital gains for the financial institutions we work with. As a Pharma strategic investor, TVI aims to provide support and guidance to entrepreneurs and early-stage companies driving concepts from preclinical through clinical proof of concept. We also strive to forge active, collaborative interactions that result in synergies with Takeda’s considerable R&D resources. TVI is based in Palo Alto, California and is actively seeking global investment opportunities. Our goal is to build a portfolio of strategic investments, with an immediate emphasis on cardiometabolic, central nervous system, chronic inflammatory and immune modulation, and oncology therapeutic domains. Our focus also includes new platforms for drug target and biomarker identification, regenerative medicines, innovative vaccines technologies and delivery systems for novel protein and peptide therapeutics. TVI currently does not invest in diagnostics platforms, medical technology and devices or anti-infective products.

Recent Milestones

Investments

Company Date Round Size Participants
Hookipa Biotech 11/2013Series B€20M5
Heptares Therapeutics 6/2013Series B$21M2
ArmaGen Technologies 11/2012Series A$17M4
Juventas Therapeutics 7/2012Series B$22.2M8
Redwood Bioscience 6/2011Venture Round1
Naurex 5/2011Series A$18M6
Lectus Therapeutics 2/2006Series A£8.2M4
Symphogen 1/2006Series D$25M6

Videos

Sources

  1. Hookipa Biotech Raises €20M in Series B Equity Financing (finsmes.com) [edit]
  2. Heptares Therapeutics Raises $21M In Series B Financing (finsmes.com) [edit]
  3. ArmaGen Technologies, Inc. Announces $17 Million Series A Financing (prnewswire.com) [edit]
  4. Juventas Therapeutics Closes $22.2M Series B Financing (finsmes.com) [edit]
  5. REDWOOD BIOSCIENCE SECURES FUNDING FOR OPTIMIZED CONJUGATE DRUG DEVELOPMENT (redwoodbioscience.com) [edit]
  6. Naurex raises $18M for Ph2 depression program (fiercebiotech.com) [edit]
  7. Lectus Therapeutics closes Series A funding round raising £8.2 million (lectustherapeutics.com) [edit]
  8. Symphogen gets $25M for clinical trials for bleeding treatment (bulletin.sciencebusiness.net) [edit]
Edit This Page
Last Edited 4/1/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy